News & Events
BIO CEO & Investor Conference
When: Feb. 11th, 2019 to Feb. 12th, 2019
Where: New York, USA
Anima Biotech will participate and present at the 2019 CEO & Investor Conference.
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities.
The 5th Annual LSX World Congress
When: Feb. 5th, 2019 to Feb. 6th, 2019
Where: London, United Kingdom
Anima Biotech has been invited to participate in a fireside chat titled, “Structuring a Win-Win Platform Technology Deal,” during the 5thAnnual LSX World Congress to share its expertise in identifying, fostering and establishing mutually beneficial collaborations within the life sciences industry.
The conference is the new name for the Biotech and Money/Medtech and Money World Congress. The meeting is a high-caliber, senior executive, two-day conference and partnering event providing the education, strategies, solutions and contacts that life science executives need to enable more effective investment, planning and strategic growth within their businesses.
Biotech Showcase 2019
When: Jan. 7th, 2019 to Jan. 9th, 2019
Where: San Francisco, USA
Anima Biotech will participate and present at Biotech Showcase 2019.
The investor and networking conference for public and private biotech companies to meet with and present to investors and pharmaceutical executives during the course of the healthcare industry's most important week of the year.
Anima Biotech named U.S. deal of the year winner at LifestarsTM Life Science Awards
When: Nov. 20th, 2018
Award recognizes the transformative potential of Anima’s $1B+ collaboration with Lilly.
Anima Biotech, the leader in the discovery of drugs that specifically control protein translation, has been named winner of the “U.S. Deal of the Year” award at the 2018 Lifestars AwardsTM.
“We are delighted to receive this award, which recognizes the power and potential of our Translation Control Therapeutics platform,” said Yochi Slonim, co-founder and chief executive officer of Anima Biotech. “Our deal with Lilly further validates our approach and our partnering strategy of creating exclusive collaborations around our partners’ chosen targets.”
“Lifestars presented a fantastic opportunity to bring together a deserved audience and highlight the advances being made in our industry. It’s a testament to Anima Biotech’s efforts that this year’s judging faculty commended them in this manner,” said Neil Darkes, Co-CEO, LSX Ltd. And Lifestars.
The international awards brought together more than 300 global life science leaders, investors and deal makers and key stakeholders from the wider ecosystem to recognize the achievements of the industry. Twenty awards were presented during a prestigious gala dinner hosted at the Honourable Artillery Company in London, UK and will support UNICEF UK as the official Charity beneficiary. Lifestars formed a signature, evening networking function during the Jefferies Annual Healthcare Conference week in London, Europe's largest healthcare investment banking conference.
The Lifestars Awards are organised by LSX, an influential community of senior life science decision makers. Through impactful events, powerful thought leadership content and unique networking opportunities, LSX exists to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare. For more information please visit www.lsxleaders.com/lifestars-awards
About Anima Biotech
Anima Biotech is advancing Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against many diseases. Anima's platform uses patented biology to monitor the process of mRNA translation by ribosomes. Proprietary, cloud-based analysis software then identifies drug candidates that specifically modulate the production of target proteins. We are advancing an internal pipeline across multiple therapeutic areas of high need and partner with Pharma in exclusive collaboration deals around their targets. Our approach has been validated through our $1B+ collaboration with Lilly, 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations.
Jefferies 2018 London Healthcare Conference
When: Nov. 14th, 2018 to Nov. 15th, 2018
Where: London, United Kingdom
Anima Biotech will participate at Jefferies 2018 London Healthcare Conference.
The event will feature leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors from the United States, Europe, Africa, Middle East, Latin America, Russia, India, Israel, China and Japan.
3rd annual Inv€$tival Showcase in partnership with Jefferies
When: Nov. 13th, 2018
Where: London, United Kingdom
Anima Biotech will participate and present at the 3rd annual Inv€$tival Showcase in partnership with Jefferies.
Biotech and Money connects corporates to capital and has partnered with Jefferies for Inv€$tival to showcase the latest investable private and public life science opportunities.
When: Nov. 5th, 2018 to Nov. 7th, 2018
Where: Copenhagen, Denmark
Anima Biotech will participate and present at BIO-Europe 2018. The 24th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 3,800 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners.
SACHS Associates 2018
When: Oct. 4th, 2018 to Oct. 5th, 2018
Where: Basel, Switzerland
Anima Biotech has participated and presented at the 18th Annual Biotech in Europe Forum.
In Addition, Yochi Slonim, Anima Biotech co-founder & CEO, co-chaired the Platform Technologies & Novel Therapeutics Panel.
The Sachs Forum is recognized as the leading international stage for those interested in investing and partnering in the biotech and life science industry.
Anima Biotech Lighting The Way In Protein Translation
When: Aug. 1st, 2018
"With a new partner in Eli Lilly, Anima Biotech and its disruptive technology that controls protein translation is starting to make waves as it urges the industry to see the light."
Anima Biotech announces an exclusive collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets
When: Jul. 23rd, 2018
Anima Biotech announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima’s Translation Control Therapeutics platform.
The multi-year agreement is structured as an exclusive collaboration around several undisclosed Lilly targets. Anima will use its technology platform to discover lead candidates that are translation inhibitors of the Lilly targets. Lilly will be responsible for clinical development and commercialization of products resulting from the collaboration.
Under the terms of the agreement, Anima will receive $30 million in upfront payments and $14 million in research funding. Anima is eligible to receive up to $1.05 billion if all future development and commercial milestones are achieved. Anima will additionally be entitled to low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
“We are excited to collaborate with Lilly in the discovery of new drugs for some of the world’s most challenging diseases. Small molecule drugs work by binding to disease-causing proteins to modify their chemical activity but most proteins lack accessible binding sites and as result, many diseases remain without effective treatments. Anima’s Translation Control Therapeutics platform is a new strategy against these undruggable target proteins. Rather than attempt to drug them after they are already made, we discover drugs that work one step before, by inhibiting (decreasing) or increasing the actual production by ribosomes of those proteins. This different approach is based on our novel science and patented technology and we believe it can lead to many new drugs” said Yochi Slonim, Anima Biotech’s co-founder and CEO.
About Anima Biotech:
Anima Biotech is pioneering Translation Control Therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against hard and undruggable
targets. Strategically structured for collaborations with multiple pharma partners, Anima's cloud based platform combines new biology with proprietary image analysis and high performance big data software. Its underlying technology is protected by 5 granted patents and its science is backed by 14 peer-reviewed publications that resulted from a network of 17 academic collaborations. The platform was validated by Anima's fast growing pipeline programs in multiple therapeutic areas including Fibrosis, Viral infections, Oncology and Neuroscience.